WVE obesity drug Phase 1 data disappoints, stock hits 10-month low

Wave Life Sciences stock plummeted over 55% after Phase 1 data for its obesity drug WVE-007 showed only 1% total weight loss. While visceral fat dropped 14%, the overall result disappointed investors, breaking the 200-day moving average. The company plans a Phase 2a study in Q2 2026 to achieve greater fat loss.